AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 12 |
Market Cap | 4.02B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.85 |
PE Ratio (ttm) | -7.21 |
Forward PE | n/a |
Analyst | Buy |
Ask | 13.3 |
Volume | 161,262 |
Avg. Volume (20D) | 116,406 |
Open | 13.16 |
Previous Close | 13.22 |
Day's Range | 13.16 - 13.41 |
52-Week Range | 9.15 - 18.00 |
Beta | undefined |
About ALVO
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque...
Analyst Forecast
According to 1 analyst ratings, the average rating for ALVO stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 35.03% from the latest price.
Next Earnings Release
Analysts project revenue of $87.50M, reflecting a 63.89% YoY growth and earnings per share of -0.01, making a -99.18% decrease YoY.